Long intergenic non-protein coding RNA 1087 (LINC01087)

Long intergenic non-protein coding RNA 1087 (LINC01087; alias ERLC1) is a human long non-coding RNA (lncRNA) named for its position in the genome outside protein-coding regions[1][5]. It is transcriptionally regulated by estrogen receptor alpha (ERα) and shows tissue-specific upregulation in breast cancer, where it modulates ERα signaling by stabilizing ESR1 mRNA through interactions with microRNAs such as miR-129 and miR-548n[2][3][4][6]. Experimental and computational studies establish its role in cancer cell proliferation, apoptosis, and development of resistance to antiestrogen therapies such as tamoxifen[2][3]. LINC01087 operates as part of a complex regulatory network with various miRNAs and protein-coding genes, offering potential for biomarker development and future therapeutic targeting in breast cancer[3]. Its molecular classification is as an intergenic long non-coding RNA, and ongoing research aims to clarify its role in signaling pathways and malignancy progression[7]. If further structured detail or additional aliases/family assignments are needed, primary reference [1] ("GeneCards") and [5] ("BioGPS") provide standardized metadata on LINC01087.

Other names

ERLC1ERα-regulated long noncoding RNA 1ERalpha-regulated long noncoding RNA 1LINC01087

For drugs like tamoxifen, palbociclib, and fulvestrant, LINC01087 upregulation confers resistance; targeting LINC01087 (e.g., through RNA interference) restores drug sensitivity, suggesting potential strategies for overcoming antiestrogen resistance. LINC01087 may act by stabilizing estrogen receptor alpha (ESR1) mRNA, thus amplifying ERα signaling. Functions as a ceRNA (competing endogenous RNA) that sequesters microRNAs (notably miR-129, miR-548n), impacting other tumor-relevant pathways.